What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings?

Belite Bio, Inc (NASDAQ:BLTE) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Belite Bio in a research report issued on Wednesday, May 21st. HC Wainwright analyst Y. Chen anticipates that the company will post earnings per share of ($0.49) for the quarter. HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio’s Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.49) EPS and Q4 2026 earnings at ($0.49) EPS.

BLTE has been the subject of a number of other reports. Benchmark reissued a “buy” rating and issued a $80.00 price target on shares of Belite Bio in a research note on Wednesday, March 26th. Wall Street Zen downgraded Belite Bio from a “hold” rating to a “sell” rating in a report on Thursday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Belite Bio in a research report on Thursday, May 15th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Belite Bio currently has an average rating of “Moderate Buy” and an average price target of $96.67.

Belite Bio Trading Down 5.6%

NASDAQ:BLTE opened at $61.00 on Friday. The company has a 50-day moving average price of $61.42 and a 200-day moving average price of $62.94. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -54.95 and a beta of -1.48. Belite Bio has a 12 month low of $43.70 and a 12 month high of $86.53.

Belite Bio (NASDAQ:BLTE) last released its quarterly earnings results on Monday, March 17th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02).

Institutional Trading of Belite Bio

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Advisors Preferred LLC purchased a new position in Belite Bio during the 4th quarter valued at about $52,000. GAMMA Investing LLC grew its holdings in Belite Bio by 43.3% in the first quarter. GAMMA Investing LLC now owns 1,849 shares of the company’s stock worth $122,000 after purchasing an additional 559 shares during the period. BNP Paribas Financial Markets bought a new position in shares of Belite Bio during the fourth quarter valued at approximately $155,000. JPMorgan Chase & Co. increased its stake in shares of Belite Bio by 7,122.7% during the third quarter. JPMorgan Chase & Co. now owns 6,356 shares of the company’s stock valued at $298,000 after purchasing an additional 6,268 shares in the last quarter. Finally, XTX Topco Ltd lifted its holdings in shares of Belite Bio by 30.9% during the fourth quarter. XTX Topco Ltd now owns 7,062 shares of the company’s stock valued at $446,000 after purchasing an additional 1,668 shares during the last quarter. 0.53% of the stock is owned by hedge funds and other institutional investors.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.